Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð...
Transcript of Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð...
![Page 1: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/1.jpg)
Melanoma: valutazione critica
Maria Teresa Fierro
![Page 2: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/2.jpg)
MELANOMA METASTATICO LINEE GUIDA 2014:
![Page 3: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/3.jpg)
![Page 4: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/4.jpg)
![Page 5: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/5.jpg)
![Page 6: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/6.jpg)
![Page 7: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/7.jpg)
![Page 8: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/8.jpg)
![Page 9: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/9.jpg)
![Page 10: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/10.jpg)
![Page 11: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/11.jpg)
![Page 12: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/12.jpg)
![Page 13: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/13.jpg)
![Page 14: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/14.jpg)
![Page 15: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/15.jpg)
COMBI-d
![Page 16: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/16.jpg)
![Page 17: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/17.jpg)
![Page 18: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/18.jpg)
![Page 19: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/19.jpg)
![Page 20: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/20.jpg)
![Page 21: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/21.jpg)
QUALI STRATEGIE FUTURE?
![Page 22: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/22.jpg)
QUALI STRATEGIE FUTURE?
![Page 23: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/23.jpg)
QUALI STRATEGIE FUTURE?
![Page 24: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/24.jpg)
![Page 25: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/25.jpg)
La combinazione dei checkpoint inibitori con BRAF + MEK inibitori è fattibile e tollerabile
Non è stata identificata la «maximum tolerated dose»
Tossicità consistenti con i noti profili di safety dei diversi farmaci
Non esacerbazione degli immune-related AEs
Markers di immuno-attivazione in tutte le coorti dopo terapia
Attività clinica precoce in tutte le coorti, la maggior parte dei pazienti ha risposte ongoing
E’ troppo presto per valutare concurrent versus sequencing doses di Trametinib e MED14736
I pazienti BRAF mutati trattati con anti BRAF+ anti MEK mostrano la maggior attivazione immunitaria e la maggior risposta clinica
![Page 26: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/26.jpg)
![Page 27: Melanoma: valutazione critica - Rete Oncologica...AJCC M stage =316 -315 YVO t Q3W 'avo Treat unoð Ntvo 3 Fl.-matched placebo tox.ctty for doses placebo N N 'Versed PO-C assay SS](https://reader033.fdocuments.net/reader033/viewer/2022060506/5f1f0d3f4c91064bf53f7148/html5/thumbnails/27.jpg)
Grazie per l’attenzione